LifeSci Venture Partners

Time 2022-09-10 11:29:20

Web Name: LifeSci Venture Partners

WebSite: http://www.lifesciventure.com

ID:310522

Keywords:

LifeSci,Venture,Partners

Description:

ABOUT TEAM PORTFOLIO NEWS CONTACT

Collaborative Capital to Accelerate Medical Breakthroughs

LIFESCI VENTURE PARTNERS

In-depth scientific research drives long term conviction and support through company building, private financing and public markets.

Healthcare Statistical Snapshot $4.2 TRILLION

2021 forecasted US national health expediture

Source : Statista $36.6 BILLION

Biotech VC funding in 2020
45% increase since 2019

Source : McKinsey 170.6 Billion

Total value of healthcare deals in 2020
84% increase since 2019

Source : McKinsey OUR INVESTMENT APPROACH Transformational Business Models We seek out companies which aim to reshape medical care and the healthcare system through novel approaches to molecular medicine, technology or healthcare delivery. Collaborate with Visionary Management Teams We partner with dynamic entrepreneurs and scientists and assist in executing long term business plans. Mid/Late Stage Venture We principally invest in companies which have achieved proof of concept and plan to transition to the public markets within 24 months. The LifeSci Partner Platform is a leading global healthcare consultancy that
provides a unique support system for our portfolio companies. Friendly Capital Flexible capital structure and friendly terms to support our high growth portfolio companies Rigorous Due Diligence Process Long term, high conviction investor, built on thorough scientific and financial expertise Unique Support for our Portfolio Companies Leverage the global LifeSci Partners network to drive value creation and accelerate business plans

The LifeSci team played an integral role in the formation and successful launch of Engage Therapeutics. At all times, I considered them part of my team. From the beginning, LifeSci guided me through the investor story, outreach process and strategy for closing.

Greg Mayes, CEO ENGAGE THERAPEUTICS

We are honored by the magnitude of support from such an impressive syndicate of investors, especially during these turbulent times.

Jonathan Lim, CEO ERASCA

We are thrilled to have an incredibly strong, committed network of investors and plan to continue extending our leadership in the decentralized clinical trial market.

David Coman, CEO SCIENCE 37 TEAM Paul Yook Partner & CIO Ryan Cinalli, PhD Chief Scientific Officer Ira Kalfus, MD Chief Medical Officer Andrew McDonald, PhD Partner Michael Rice Partner Julie Mauser Director, Business Development Mark Charest Venture Partner Brittany Amendola, CPA Controller Sophie Jabban Analyst LIFESCI PARTNERS PLATFORM LifeSci Partners is a global healthcare advisory boutique with 200 experienced investment and science professionals LS Associates On Demand C-Level Leaders LifeSci Advisors Investor Relations Services LifeSci Communications Public Relations and Communications LifeSci Search Global Executive Recruiting LifeSci Capital Investment Banking LifeSci Partnering and Analytics Strategic Partnerships & Market Analytics PORTFOLIO COMPANIES

MOMA THERAPEUTICS

CLADE THERAPEUTICS

LARONDE

ATTRALUS

ANTIOS THERAPEUTICS

PYXIS ONCOLOGY

OMEGA THERAPEUTICS

IRIDIA

BRIGHT MINDS BIOSCIENCES

MANA THERAPEUTICS

CARIBOU BIOSCIENCES

EGENESIS

CENTESSA PHARMACEUTICALS

BIONOMICS

RAYZEBIO

VIRACTA

AUGMEDIX

CYBIN

SENTI BIOSCIENCES

ALLIEVEX

SCIENCE37

August 2020, Series D-1

Science 37 is a decentralized CRO making the promise of v...

ATHIRA

ERASCA

March 2019, Series A April 2020, Series B

Erasca is a San Diego based biotech company creating a new generation of onc...

CALA HEALTH

May 2019, Series C

Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disea...

BETA BIONICS

January 2019, Series B

Beta Bionics is a medical device company developing the breakthrough iLet system which combines...

AKERO

December 2018, Series B

Akero is a biotechnology company focused on serious metabolic diseases with a lead program, AK...

ATTUNE

June 2018, Series B

Attune is a clinical-stage biotechnology company focused on novel small-molecule therapeutics for...

METACRINE

June 2018, Series C

Metacrine is a San Diego based biotechnology company with exceptional chemistry capabilities and a...

ORASIS

March 2018, Series B

Orasis is a clinical-stage pharmaceutical company developing an innovative eye drop for the treat...

NOVUS

March 2018, At-the-Market
Nasdaq: NVUS

Novus is a specialty pharma company focused on disorders of the near, nose...

COLUMBIA

January 2018, Series D
November 2018, RTO

Columbia Care is one of the largest medical cannabis manufacturers and...

ALLAKOS

November 2017, Series B
July 2018, IPO -Nasdaq: ALLK

Allakos is developing AK002, a first-in-class antibody...

BIOLINQ

ROCKET

March 2017, Series B
January 2018, NASDAQ: RCKT

Rocket Pharma is developing...

ENGAGE

September 2017, Series A

Engage is developing Staccato® Alprazolam, a small, easy-to-use hand-held drug-device com...

NEWS MOMA Therapeutics Announces $150 Million Series B Financing May 10, 2022 Clade Therapeutics Raises $87 Million Series A Financing to Realize the Potential of Cell Therapy November 3, 2021 Biolinq Raises $100 Million, Unveils Micro-Sensing Technology in the Skin November 2, 2021 Science 37 Closes Business Combination with LifeSci Acquisition II Corp. and Will Begin Trading on Nasdaq as SNCE October 7, 2021 Attralus Closes $116 Million Series B Financing September 8, 2021 Revelation Biosciences, Inc. to Become Publicly Traded Through a Merger with Petra Acquisition, Inc. August 30, 2021 Laronde Attracts $440M in First External Financing to Further Advance Endless RNA™ Platform August 30, 2021 Omega Therapeutics Announces Pricing of Initial Public Offering July 29, 2021 Caribou Biosciences Announces Pricing of Upsized Initial Public Offering July 22, 2021 Erasca Announces Pricing of Upsized Initial Public Offering July 15, 2021 Centessa Announces Pricing of Initial Public Offering May 27, 2021 Science 37 to Become Publicly Listed via Merger with LifeSci Acquisition II Corp. May 7, 2021 Antios Therapeutics Raises $96 Million in a Series B Financing April 12, 2021 Pyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics March 30, 2021 Omega Therapeutics to Advance Pipeline and Platform Development with $126 Million in Additional Financing March 30, 2021 Iridia Raises $24 Million in Series B Funding March 16, 2021 Caribou Biosciences Raises $115M Series C Financing to Advance Next-Generation CRISPR Technologies March 3, 2021 eGenesis Announces $125 Million Series C Financing March 2, 2021 Bright Minds Biosciences Inc. Announces Pricing of Public Marketed Offering of Units February 23, 2021 Centessa Pharmaceuticals Launches with $250 Million Series A Financing and Unveils a New Kind of Pharmaceutical R&D Model February 16, 2021 $16 Million Capital Raise to Progress Bionomics BNC210 PTSD Trial February 10, 2021 Augmedix Launches Tech-Enabled Service Within Emergency Departments to Provide Real-Time Support and Optimize Clinician Workflow January 14, 2021 MANA Therapeutics Launches with $35 Million Series A Financing January 8, 2021 Senti Bio raises $105 million for its new programmable biology platform and cancer therapies January 6, 2021 Erasca Unveils Its First Strategy to Erase Cancer January 6, 2021 RayzeBio Completes $105M Series B Financing to Advance Targeted Radiopharmaceuticals for Cancer December 8, 2020 Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement November 30, 2020 SK Biopharmaceuticals and LifeSci Venture Partners Forge Ties for Open Innovation November 2, 2020 Cala Health Receives FDA Breakthrough Device Designation October 22, 2020 Allakos Announces Publication of Results from the Phase 2 Study October 21, 2020 CYBIN and Clarmin Announce Closing of CDN$45 Million Oversubscribed Private Placement October 19, 2020 Athira Pharma Announces Pricing of Initial Public Offering September 17, 2020 Metacrine Announces Pricing of Initial Public Offering September 15, 2020 Orasis Raises $30 Million to Advance the Clinical Development of Novel Treatment for Presbyopia September 10, 2020 Science 37 Raises $40 Million to Extend Its Leadership in the Decentralized Clinical Trial Market August 20, 2020 UCB Acquires Engage Therapeutics June 5, 2020 Athira Pharma Closes $85 Million Series B Financing June 5, 2020 Erasca Raises $200 Million Series B Financing April 27, 2020 Akero Therapeutics Announces Pricing of Initial Public Offering June 19, 2019 Cala Health Raises $50 Million Series C Funding May 21, 2019 Attune Pharmaceuticals Announces $23M Series B Financing to Advance ATN249 for the Treatment of HAE January 23, 2019 Beta Bionics Announces Final Closing of Its $63 Million Series B Financing January 11, 2019 Akero Therapeutics Announces $70 Million in New Financing to Advance Therapeutic Pipeline for NASH, Serious Metabolic Diseases December 12, 2018 Allakos Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares July 24, 2018 Metacrine Completes $65 Million Series C Financing June 6, 2018 Orasis Pharmaceuticals Closes $13 Million Series B Financing June 5, 2018 Engage Therapeutics Shareholder Update Letter May 7, 2018 Rocket Pharmaceuticals and Inotek Pharmaceuticals Complete Merger Transaction January 4, 2018 Allakos Secures $100 Million In Series B Financing December 13, 2017 Biolinq Completes $10M Series A Financing November 27, 2017 Engage Therapeutics Announces $23 Million Series A September 27, 2017 Rocket Pharma announces merger into Inotek September 12, 2017 STATNews: A veteran biopharma executive (Engage) August 17, 2017 LifeSci Venture Partners 250 West 55th Street, 34thFloor
New York, NY 10019 General Inquiries +1 646.889.1200 info@lifesciventure.com Ira Kalfus, MD Chief Medical Officer

Dr. Kalfus was Chief Medical Officer at Thar Pharmaceuticals until its acquisition by Grunenthal in 2016. He was previously Vice President of Medical Affairs at Lev Pharmaceuticals, where he led the clinical development for Cinryze, the first HAE prophylaxis therapy, approved by the FDA in 2008. Upon the acquisition of Lev by ViroPharma Inc. in 2008, he consulted on the Cinryze commercial launch and expansion as well as investor relations activities for ViroPharma. Dr. Kalfus is consulting Medical Director at RedHill Biopharma Ltd. and directs two phase III clinical programs. His other positions have included Aetna/US Healthcare (Medical Director), Hillside Medical Associates (Internist), and Long Island Jewish Medical Center (President of the Staff Society and Chairman of Performance Improvement). Dr. Kalfus completed residency in Internal Medicine at Long Island Jewish Medical Center and graduated from Albert Einstein College of Medicine with an M.D. and Columbia University with a B.A. in Biology.

Visit Homepage

TAGS:LifeSci Venture Partners

<<< Thank you for your visit >>>

Hot Websites